Kailera Debut Points To New Life In Biotech Ipos
Kailera delivered an eye-catching stock market debut, offering fresh evidence that investor appetite for obesity-drug developers remains strong even after a difficult stretch for biotechnology listings. The company sold roughly 39 million

